{"id":309,"date":"2026-02-11T10:15:07","date_gmt":"2026-02-11T10:15:07","guid":{"rendered":"https:\/\/www.europesays.com\/ch\/309\/"},"modified":"2026-02-11T10:15:07","modified_gmt":"2026-02-11T10:15:07","slug":"roche-says-experimental-drug-helped-slow-disability-in-progressive-multiple-sclerosis-study-roche-holding-otcrhhby","status":"publish","type":"post","link":"https:\/\/www.europesays.com\/ch\/309\/","title":{"rendered":"Roche Says Experimental Drug Helped Slow Disability In Progressive Multiple Sclerosis Study – Roche Holding (OTC:RHHBY)"},"content":{"rendered":"

Roche Holdings AG (OTC:<\/a>RHHBY<\/a>) on Monday shared new late-breaking data from the Phase 3 FENtrepid study of the investigational Bruton’s tyrosine kinase (BTK) inhibitor fenebrutinib.<\/p>\n

Fenebrutinib is an investigational, oral, highly selective, reversible (non-covalent) Bruton’s tyrosine kinase (BTK) inhibitor developed by Roche.<\/p>\n

It blocks both B-cell and microglia activation, making it a candidate for treating multiple sclerosis (MS) and other autoimmune diseases by crossing the blood-brain barrier to reduce inflammation.<\/p>\n

These data follow Roche’s announcement in November 2025 that the FENtrepid study and the first<\/a> of two Phase 3 relapsing multiple sclerosis (RMS) studies (FENhance 2) met their primary endpoints.<\/p>\n

Once the second RMS study (FENhance 1) has read out, which is expected in the first half of 2026, data from all Phase 3 fenebrutinib<\/a> trials will be submitted to regulatory authorities.<\/p>\n

Reduces Disability Progression<\/p>\n

The trial met<\/a> its primary endpoint of non-inferiority compared to Ocrevus (ocrelizumab) in reducing disability progression in patients with primary progressive multiple sclerosis (PPMS).<\/p>\n

Fenebrutinib showed a 12% reduction in the risk of disability progression compared to Ocrevus, the only approved medicine for PPMS, as measured by the time to onset of 12-week\u00a0composite confirmed disability progression (cCDP12) with curves separating as early as 24 weeks.<\/p>\n

A consistent treatment effect on cCDP12 was observed across patient subgroups and for the entire treatment duration.<\/p>\n

The cCDP12 primary endpoint included the confirmed disability progression (CDP) based on the Expanded Disability Status Scale (EDSS) for functional disability, the timed 25-foot walk (T25FW) for walking speed and the nine-hole peg test (9HPT) for upper limb function.<\/p>\n

The strongest treatment effect was observed on the risk of worsening on the 9HPT by 26% compared to Ocrevus.<\/p>\n

First Potential Scientific Breakthrough In Decade<\/p>\n

“Fenebrutinib represents the first potential scientific breakthrough for the PPMS community in over a decade, demonstrating a meaningful clinical benefit in reducing disability progression in a study versus the only approved treatment in PPMS,” said Levi Garraway, Roche’s Chief Medical Officer and Head of Global Product Development.<\/p>\n

Additionally, a post-hoc analysis showed that fenebrutinib was superior to Ocrevus on a composite endpoint including two of the three components of cCDP12 (EDSS and 9HPT), with a 22% reduction in risk.<\/p>\n

Results were shared at the\u00a0Americas Committee for Treatment and Research in Multiple Sclerosis (ACTRIMS) Forum 2026.<\/p>\n

Roche shared new Phase 3 data showing its oral MS drug fenebrutinib reduced disability progression versus Ocrevus in patients with primary progressive multiple sclerosis.<\/p>\n

AZN Price Action: Roche shares closed higher by 1.02% at $57.70 on Friday, according to Benzinga Pro data<\/a>.<\/p>\n

Photo by OleksSH via Shutterstock<\/p>\n","protected":false},"excerpt":{"rendered":"Roche Holdings AG (OTC:RHHBY) on Monday shared new late-breaking data from the Phase 3 FENtrepid study of the…\n","protected":false},"author":2,"featured_media":310,"comment_status":"","ping_status":"","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[124],"tags":[342,344,346,343,345,341,340,134,347,348],"class_list":{"0":"post-309","1":"post","2":"type-post","3":"status-publish","4":"format-standard","5":"has-post-thumbnail","7":"category-roche","8":"tag-category-biotech","9":"tag-category-health-care","10":"tag-category-movers","11":"tag-category-news","12":"tag-category-top-stories","13":"tag-cms-wordpress","14":"tag-pageisbzpro-bz","15":"tag-roche","16":"tag-symbol-rhhby","17":"tag-tag-stories-that-matter"},"share_on_mastodon":{"url":"","error":""},"_links":{"self":[{"href":"https:\/\/www.europesays.com\/ch\/wp-json\/wp\/v2\/posts\/309","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/www.europesays.com\/ch\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/www.europesays.com\/ch\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/www.europesays.com\/ch\/wp-json\/wp\/v2\/users\/2"}],"replies":[{"embeddable":true,"href":"https:\/\/www.europesays.com\/ch\/wp-json\/wp\/v2\/comments?post=309"}],"version-history":[{"count":0,"href":"https:\/\/www.europesays.com\/ch\/wp-json\/wp\/v2\/posts\/309\/revisions"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/www.europesays.com\/ch\/wp-json\/wp\/v2\/media\/310"}],"wp:attachment":[{"href":"https:\/\/www.europesays.com\/ch\/wp-json\/wp\/v2\/media?parent=309"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/www.europesays.com\/ch\/wp-json\/wp\/v2\/categories?post=309"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/www.europesays.com\/ch\/wp-json\/wp\/v2\/tags?post=309"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}